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p27isregardedasacyclin-dependentkinaseinhibitoroftheG1-to-Scellcycleprogressionbysuppressingthekinaseactivityofcyclin/
cyclin-dependent kinase complex. This study aimed to investigate p27 expression in the normal endometrium and endometrioid
adenocarcinomaoftheuterinecorpusandthecorrelationofitsexpressionwithcellproliferationandclinicopathologicalparameters.
Tissue samples of 127 endometrioid adenocarcinomas and 15 normal endometria were used in the study. Immunohistochemical
staining for detecting p27 and Ki-67 was performed by the labelled streptavidin-biotin method on formalin-ﬁxed and parafﬁn-
embedded tissue samples. The expression was given as the labelling index, which indicates the percentage of positive nuclei. p27
staining was observed in the nuclei of the glandular cells in the functional layer of the secretory phase endometrium, whereas it was
negative in those of the proliferative phase. In endometrioid adenocarcinomas, the labelling index of p27 expression paradoxically
increased more signiﬁcantly in the higher histological grades and was correlated with that of Ki-67. The high level of p27 expression
was associated with clinicopathological parameters such as FIGO stage, lymph node metastasis, lymphovascular space involvement
and myometrial invasion. High p27 expression was linked to higher grades of endometrioid adenocarcinoma, cell proliferation and
some clinical prognostic factors. These results indicate that p27 might be an indicator of poor prognosis.
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Cyclin-dependent kinase inhibitor (CKI) inhibits the cell cycle
progression by suppressing the kinase activity of a variety of
cyclin/cyclin-dependent kinase (cdk) complexes (Sherr, 1996).
Abnormal expression of CKI is thought to play an important role
in tumorigenesis and the progress of tumours.
CKIs are classiﬁed into two major families; the Ink4 family and
the Cip/Kip family. P27 belongs to the Cip/Kip family and binds
preferentially to the cyclin E/cdk2 and cyclin D/cdk4 complexes,
and inhibits the G1-to-S progression (Russo et al, 1996). p27
knock-out mice sustain a variety of abnormalities including
increased body size, multiple organ hyperplasia, pituitary tumour,
and sterility due to underdeveloped ovaries (Nakayama et al,
1996). Therefore, p27 is predicted to act as a tumour suppressor.
It has been generally accepted that decreased p27 expression is
related to poor prognosis in tumours of different histogenesis
including lung (Kawana et al, 1998), oesophageal (Singh et al,
1998), colon (Loda et al, 1997), breast (Gillett et al, 1999), ovarian
(Masciullo et al, 1999) and prostate cancers (Yanping et al,
1997).In contrast, it has also been reported that increased p27
expression is correlated with poor prognosis of the oesophagus
(Anayama et al, 1998) and colon carcinoma (Cheng et al, 1999).
In fact, it is not clear whether p27 expression is correlated posi-
tively or inversely with prognosis.
In the endometrium, it was reported that p27 was expressed in
the secretory phase, but less in the proliferative phase (Shiozawa et
al, 1998; Bamberger et al, 1999). Its expression was also higher in
endometrial hyperplasia than in the proliferative phase and was
signiﬁcantly increased when the former was treated with medroxy-
progesterone acetate (Shiozawa et al, 1998). Two studies mentioned
that p27 was strongly reduced in endometrial carcinoma (Ahn et
al, 1998; Bamberger et al, 1999), whereas a recent study showed
a trend of increased p27 protein staining with high grade endome-
trial carcinoma (Nycum et al, 2001). p27 expression in endometrial
carcinoma still remains contradictory. This study aimed to investi-
gate p27 expression by immunohistochemical staining and the
correlation of its expression with histological grades, cell prolifera-
tion and clinicopathological parameters in endometrioid adeno-
carcinoma of the uterine corpus.
MATERIALS AND METHODS
Materials
Tissue samples of 127 cases of endometrioid adenocarcinomas
consisting of 73 well-differentiated adenocarcinomas (G1), 26
moderately-differentiated ones (G2), 28 poorly-differentiated ones
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www.bjcancer.com(G3)) and 15 cases of normal endometrium (ﬁve with proliferative
phase, 10 with secretory phase) were surgically obtained at Kitasato
University Hospital between 1986 and 2000. Informed consent was
obtained from all of the patients. Pathological diagnosis was classi-
ﬁed according to the FIGO classiﬁcation (FIGO, 1989). The
patients’ ages ranged from 30 to 83 years with the median age of
56 years. No patients had received either adjuvant chemotherapy
or radiotherapy before surgery.
Immunohistochemistry
Immunohistochemical staining for p27 and Ki-67 were performed
with the labelled streptavidin-biotin method (DAKO, Kyoto,
Japan). Tissue samples ﬁxed in 10% formalin and embedded in
parafﬁn were sectioned to 3 mm and deparafﬁnized in xylene.
Endogenous peroxidase activity was blocked by 3% hydrogen
peroxide for 30 min. Then, antigen retrieval was performed by
autoclave at 1218C for 15 min in 0.1 mM citrate buffer (pH 6.0).
After being incubated with 10% normal swine serum for 30 min,
mouse monoclonal anti-human p27 antibody (clone 1B4, 1:200,
Novocastra, Newcastle, UK) and rabbit polyclonal anti-human
Ki-67 antibody (1:50 DAKO, Kyoto, Japan) were applied to the
slides overnight at 48C, respectively. As negative controls, normal
mouse or rabbit serum at the same dilution was used. Diamino-
benzidine reaction was done for visualisation of the signal and
Mayer’s haematoxylin was used for counterstaining.
The percentage of positive nuclear staining of p27 was evaluated
by counting at least 1200 cells in high power ﬁelds independently
by two observers and expressed as the labelling index (LI). They
were blinded as to the pathological parameters. Interobserver varia-
tion was addressed by averaging the individual values. Its variation
usually did not differ by more than 10%.
Measurement of oestrogen receptor (ER) and progesterone
receptor (PR)
Oestrogen receptor (ER) and progesterone receptor (PR) in
tumour tissue freshly obtained at surgery were measured
using the radioreceptor assay system of Kitasato Biochemical
Laboratory (Kanagawa, Japan). ER and PR were deﬁned as
positive when gross bound count/non-speciﬁc bound count
42, Kd51n M l
71 and (straight line recurrence coefﬁcient)
40.9.
Statistical analysis of immunostaining
Statistical analysis of the correlation between LI of p27 and
Ki-67 in the same patient was conducted by the Spearmann
rank correlation test. The Mann–Whitney U-test was used
to examine the correlation between LI of p27 and clinico-
pathological parameters. P-values less than 0.05 were
considered signiﬁcant.
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Figure 1 Immunohistochemical staining of p27 in normal endometrium. In the proliferative phase, the nuclei of the glandular cells in the functional layer
are negative for p27 (A). In the secretory phase, the nuclei of the superﬁcial lining cells and the glandular cells in the functional layer show positive for p27
(B). (Original magniﬁcation, 6200).
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p27 expression in normal endometria
In the proliferative phase, the glandular cells in the functional layer
were negligible for p27 (Figure 1A). In the secretory phase, the
nuclei of the superﬁcial lining cells and the glandular cells of the
functional layer were positive for p27 (Figure 1B).
p27 expression in endometrioid adenocarcinomas
p27 staining was positive in the nuclei of endometrioid adenocar-
cinomas and the positive rate of all cases was 97.6% (124 out of
127 cases). The LIs of p27 expression in G1, G2 and G3 of endo-
metrioid adenocarcinomas were 55.1+25.0, 64.4+15.1 and
75.0+10.7%, respectively. The LIs increased signiﬁcantly in the
higher histological grades (Table 1); Figure 2A,B).
Although weak in comparison with the nuclei, p27 staining in
the cytoplasm was also observed in 67.1% of G1 cases (49 out of
73 cases), 61.5% of G2 (16 out of 26 cases) and 25.0% of G3
(seven out of 28 cases), respectively.
The correlation of p27 expression with Ki-67 expression
Positive staining of KI-67 was observed in the nuclei of endome-
trioid adenocarcinomas of the uterine corpus. LI of p27
expression was signiﬁcantly correlated with that of Ki-67
(Rs=0.226, P=0.017) (Figure 3).
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Table 1 Correlation between p27 expression and clinicopathological
parameters in endometrial adenocarcinoma of the uterine corpus
Clinicopathological No. of p27 LI (%)
parameters cases Mean+SD P-value
Histological grade
G1 73 55.1+25.0
a) c) a) P=0.04*
G2 26 64.4+15.1 b) P=0.03*
G3 28 75.0+10.7
b) c) P=0.001*
Stage
FIGO I 85 60.7+21.8
d) d) P=0.03*
FIGO II 12 57.9+24.1
e) e) P=0.48*
FIGO III 27 61.1+19.8
f) f) P=0.03*
FIGO IV 3 77.4+4.9
Lymph node metastasis
negative 102 57.7+22.8
P50.001* positive 13 75.8+13.2
LVSI
negative 87 56.6+23.2
P50.001* positive 30 72.2+13.3
Myometrial invasion
subserosal 112 60.2+22.0
P=0.042* serosal 6 71.9+8.7
Group
1 56 61.4+19.7
2 52 60.4+21.7 N.S.
3 16 57.8+27.9
ER
positive 56 61.1+23.0
negative 44 65.3+17.9 N.S.
PR
positive 50 63.2+21.2
negative 49 63.1+18.8 N.S.
Menopause
Pre 39 61.5+24.6
Post 88 60.7+20.1 N.S.
*P50.05: signiﬁcant. N.S.: not signiﬁcant. KI: labelling index. LVSI: lymphovascular
space involvement. Group 1: coexisting with endometrial hyperplasia. Group 2: coex-
isting with normal endometrium. Group 3: entirely replaced by carcinoma. Mann–
Whitney U-test.
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Figure 2 Immunohistochemical staining of p27 in endometrioid adeno-
carcinoma. The nuclei of G1 (A) and G3 (B) of endometrioid adenocarci-
noma show positive for p27. (Original magniﬁcation, 6400).
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Figure 3 Correlation of p27 expression with Ki-67. LI of p27 was signif-
icantly correlated with that of Ki-67 in endometrioid adenocarcinoma of
the uterine corpus.
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clinicopathological parameters
The high level of p27 expression was signiﬁcantly correlated with
the clinicopathological parameters such as FIGO stage I vs IV
(P=0.03), II vs IV (P=0.048), and III vs IV (P=0.03), lymph node
metastasis (P50.0001), lymphovascular space involvement (LVSI)
(P50.0001) and myometrial invasion (P=0.042). In contrast, it
was not correlated with Group (Group 1: coexisting with endome-
trial hyperplasia, Group 2: coexisting with normal endometrium,
Group 3: entirely replaced by carcinoma) (Ohkawara et al, 2000),
ER and PR, and menopause (Table 1).
DISCUSSION
Our study showed that p27 staining was observed in the nuclei of
the glandular cells in the secretory phase but negligible in the
proliferative phase of normal endometrium. This result is the same
as in previous reports (Shiozawa et al, 1998; Bamberger et al,
1999). Shiozawa et al (1998) suggested that a markedly increased
p27 expression induced by progesterone in the secretory phase
might develop cell growth arrest by inhibiting the cyclin E/cdk2
complex and it was a result of a persistent accumulation of p27
due to a prolonged half-life by progesterone-mediated impaired
proteolytic activity.
Surprisingly, p27 expression in endometrioid adenocarcinoma
of the uterine corpus increased signiﬁcantly in the higher histo-
logical grades in our study. Two reports on endometrial
adenocarcinoma demonstrated that decreased p27 expression
was correlated with higher histological grade (Ahn et al, 1998;
Bamberger et al, 1999). Recently, however, a trend associated
with increased p27 staining with advanced grades of endometrial
carcinoma was reported (Nycum et al, 2001). Our study showed
that p27 expression was correlated with that of Ki-67 as a
proliferative marker. Similar results of a positive correlation
between p27 expression and Ki-67 expression were reported in
the colon (Cheng et al, 1999) and lung (Shoji et al, 1999).
In some highly proliferative human breast cancer cells (Freders-
dorf et al, 1997) and Burkitt’s lymphoma cells (Barnouin et al,
1999), a high level p27 expression was seen. These results indi-
cate that p27 expressed in carcinoma may not arrest the cell
cycle progression.
A possible mechanism of p27 expression abnormality could be
considered as follows: (1) its functional abnormality may be due
to gene mutation. But no detectable cancer-speciﬁc mutations
were found in a total of 147 human tumours (Ponce-Castaneda
et al, 1995). Although polymorphism as a nucleotide substitution
of guanine for thymine (GTC?GGC) at codon 109 was found in
endometrial, uterine cervical and ovarian cancers, this polymorph-
ism is also detected in normal cells (Kawamata et al, 1995).
Deletions of the p27 gene have only been detected in B-immuno-
blastic non-Hodgkin’s lymphomas and adult T-cell leukaemias/
lymphomas (Morosetti et al, 1995); (2) There may be a quantita-
tive or structural abnormality of the cyclin E/cdk2 complex. There
are two possibilities. One is an excessive amount of the complex
beyond the inhibitory action of p27. The other is that p27 may
act controversially as an assembly factor to stabilise the complex
(Shoji et al, 1999); (3) Consumption of p27 may be trapped by
other factors such as cyclin D1 and D3, which suppressed the
formation of the complex (Fredersdorf et al, 1997; Tomoda et
al, 1999); (4) p27 degradation by the ubiquitin-proteasome path-
way in which skp2 is implicated (Carrano et al, 1999) may be
disordered. Clariﬁcation of the precise mechanism of these possi-
bilities, however, is left for a future study. Moreover, p27 may be
overexpressed by a homeostatic feedback mechanism in overex-
pressed cases of p27, since high levels of cyclin E and cdk2
expressions are observed in these cases (Kawana et al, 1998;
Cheng et al, 1999).
p27 expression in the cytoplasm has been reported in oesopha-
geal (Gillett et al, 1999), colon (Fredersdorf et al, 1997) and
ovarian carcinomas (Masciullo et al, 1999). Our analysis showed
that p27 expression in the cytoplasm of endometrioid adenocarci-
noma was reduced in the higher grade. With regard to this
mechanism, it is suggested that unstable p27 is translocated from
the nucleus to the cytoplasm by binding Jab1 as the transreporter
(Tomoda et al, 1999). Furthermore, a recent study shows that
staining in the cytoplasm rather than in the nuclei is correlated
with a recurrence and decreased survival (Singh et al, 1998). p27,
which is localized in the cytoplasm, may not play a signiﬁcant role
in the prognosis of endometrial carcinoma, since p27 expression in
endometrioid adenocarcinoma was predominant in the nuclei.
Our study showed that p27 expression in endometrioid adeno-
carcinomas was associated with prognostic factors, such as FIGO
stage, lymph node metastasis, LVSI and myometrial invasion.
There are variable views on the correlation between p27 expression
and clinicopathological factors in various tumours. For example,
low p27 expression was associated with prognostic factors in oeso-
phageal (Singh et al, 1998) and ovarian carcinomas (Masciullo et
al, 1999). It was also reportedly correlated with poor prognosis
in colon (Loda et al, 1997) and breast carcinomas (Gillett et al,
1999) by univariate or multivariate analysis. In contrast, increased
p27 expression was associated with poor prognosis in oesophageal
(Anayama et al, 1998) and colon cancers (Fredersdorf et al, 1997).
The majority of reports suggest that either high or low p27 expres-
sion is an independent prognostic factor. In endometrial
carcinoma, it was reported that p27 expression was not associated
with prognostic factors (Ahn et al, 1998; Bamberger et al, 1999;
Nycum et al, 2001), whereas in our study the high expression
was correlated with prognostic factors, since p27 protein expression
increased in high grade and was associated with cell proliferation in
our study.
p27 expression in endometrioid adenocarcinomas was not asso-
ciated with hormone-related clinicopathological situations such as
menopause, Group (Group 1: coexisting with endometrial hyper-
plasia, Group 2: coexisting with normal endometrium, Group 3:
entirely replaced by carcinoma) (Ohkawara et al, 2000), and
expression of ER or PR, although it was reportedly mediated by
a progesterone-related hormonal environment in normal endome-
trium (Shiozawa et al, 1998). A recent study showed that
antiestrogen-induced p21 and p27 via ER blocked entry of G1
phase cells into the S phase by inhibiting cyclin D1 expression
and cdk2 kinase activity in breast cancer cell lines (Watts et al,
1995). The relation between p27 expression and hormonal regula-
tion in normal and neoplastic endometrial cells is left for further
investigation.
In endometrioid adenocarcinoma of the uterine corpus, high
p27 expression was linked to higher grade and Ki-67 expression,
and may be paradoxical in the physiological action of p27. p27
expression was also correlated with clinical prognostic factors such
as FIGO stage, lymph node metastasis, LVSI and myometrial inva-
sion. Therefore, p27 expression might be an indicator of poor
prognosis. We need more time to elucidate the relation between
our results and our patients’ actual prognosis.
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